Short-course human leukocyte interferon in treatment of herpes zoster in patients with cancer.
Because of encouraging results when human leukocyte interferon was given for 5 to 7 days to treat early localized herpes zoster in patients with cancer, a small placebo-controlled, randomized, double-blind trial was set up involving only 48 h of therapy. In this trial, there was no effect on acute pain or disease progression in the primary dermatome. However, a modest but significant effect was noted in that distal cutaneous spread was diminished in the treated patients compared with the controls and the treated patients had diminished severity and duration of postherpetic neuralgia. No evidence of impairment in varicella-zoster-specific lymphocyte transformation was observed in interferon-treated patients.
D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006562:Herpes Zoster / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D007962:Leukocytes / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects; D009369:Neoplasms / Q000150:complications*
D007372:Interferons